compounded semaglutide shortage & Tirzepatide 2025: Safe Use Guide compounded semaglutide deadline As of

A phase 2 trial of Retatrutide (TripleHormone-Receptor Agonist) for obesity

The LEAN-PREP study (NCT enrolling 2025) is the first, with results expected 2026-2027

Similar patterns emerge with tirzepatide, though longer-term discontinuation data remains limited

[6] [7] These medications work by mimicking naturally occurring hormones that regulate blood glucose and appetite

Overview Retatrutide is a synthetic, long-acting triple agonist that targets three distinct hormonal receptors: the glucagon-like pep-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor (GCGR)